Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer - Concepedia

Concepedia

Publication | Closed Access

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

87

Citations

26

References

2006

Year

John T. Isaacs, David Z. Qian, Susan L. Dalrymple, Jason B. Garrison, Natasha Kyprianou, Anders Björk, Anders Olsson, Tomas Leanderson

Abstract

Based upon its robust and consistent anti-angiogenic activity and thus tumor growth, ABR-215050 has entered clinical trials for the treatment of prostate cancer.

References

	Year	Citations

Page 1